Luke Larson - 27 Dec 2022 Form 4 Insider Report for AXON ENTERPRISE, INC. (AXON)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
28 Dec 2022, 16:46:01 UTC
Prior SEC filing
07 Dec 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Luke Larson by Isaiah Fields, Attorney-in-Fact

Key filing fact

Luke Larson filed Form 4 for AXON ENTERPRISE, INC. (AXON) on 28 Dec 2022.

Key facts

  • This page summarizes Luke Larson's Form 4 filing for AXON ENTERPRISE, INC. (AXON).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 28 Dec 2022, 16:46.

Change

  • Previous filing in this sequence was filed on 07 Dec 2022.
  • Current net transaction value: -$626,157.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXON transaction

Common Stock

Sale

Transaction value
$626,157
Shares
-3,711
Change %
-1.3%
Price
$168.73
Shares after
272,917
Date
27 Dec 2022
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Securities disposed represent securities sold on the open market to settle the reporting person's tax liability incident to the vesting of restricted stock units. This sale of vested restricted stock units was executed pursuant to a filed Rule 10b5-1 plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .